KADMON

KDMN NYSE
2.170
+0.020
+0.93%
After Hours: 2.170 0 0.00% 16:35 05/24 EDT
Open
2.150
Prev Close
2.150
High
2.210
Low
2.150
Volume
584.34K
Avg Vol (3M)
809.57K
52 Week High
4.390
52 Week Low
1.880
% Turnover
0.45%
Market Cap
280.97M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers KADMON KDMN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
MORE >

Recently

Name
Price
%Change